# InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Gains 18-Month NYSE Compliance Window

Annovis Bio (NYSE: ANVS), a clinical-stage platform company developing therapies for neurodegenerative diseases including Alzheimer’s and Parkinson’s, has received formal acceptance from the New York Stock Exchange of its compliance plan addressing minimum market capitalization and stockholders’ equity requirements. The NYSE granted the company an 18-month window, beginning March 26, 2025, to regain compliance.

 During this period, Annovis Bio will continue trading on the NYSE, provided it meets the milestones outlined in the plan and adheres to all other listing requirements. The notification has no impact on the company’s operations, business activities or SEC reporting obligations.

 To view the full press release, visit https://ibn.fm/D9Yzt

 About Annovis Bio Inc.

 Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic proteins, with the goal of restoring brain function and improving the quality of life for patients.

 For more information, visit the company’s website at www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.

 NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://ibn.fm/ANVS

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-annovis-bio-inc-nyse-anvs-gains-18-month-nyse-compliance-window/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/annovis-bio-granted-nyse-compliance-extension-for-neurodegenerative-therapies/234c9978db0d6f9ad2d0c9557db4b573) 

 



[Reddit Post](https://www.reddit.com/r/BlockchainWeb3New/comments/1lg4ee6/annovis_bio_granted_nyse_compliance_extension_for/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/256/20/openuVpn.webp)